Literature DB >> 11734094

Adverse events, compliance, and changes in therapy.

R Düsing1.   

Abstract

Compliance with medical therapy represents a multifactorial problem with marked consequences for individual and public health. Among the many contributing factors, the choice of drug may also determine the degree of compliance. Various studies investigating either compliance or persistence with antihypertensive therapy using a variety of methods have suggested that adherence to therapy may show the following pattern: diuretics < beta-blockers < calcium channel blockers < ACE inhibitors. Furthermore, two recent studies have shown that therapy with angiotensin II receptor blockers may be associated with better long-term adherence than other antihypertensive monotherapies including angiotensin converting enzyme inhibitors. Since medication compliance with antihypertensive therapy, among other factors, closely correlates with the experience of side effects, it may be speculated that the different classes of antihypertensives may induce varying degrees of compliance and persistence due to their different tolerability profiles. Side effects may induce variable compliance and nonpersistence by yet another mechanism. Therapy turbulence, ie, any change in medication, is also associated with nonpersistence. Therefore, side effects may directly or indirectly (via inducing therapy turbulence) underly variable compliance and nonpersistence.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11734094     DOI: 10.1007/s11906-001-0011-0

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   5.369


  15 in total

Review 1.  Compliance with drug therapy-new answers to an old question.

Authors:  R Düsing; K Lottermoser; T Mengden
Journal:  Nephrol Dial Transplant       Date:  2001-07       Impact factor: 5.992

2.  Effect of initial drug choice on persistence with antihypertensive therapy: the importance of actual practice data.

Authors:  J J Caro; J L Speckman; M Salas; G Raggio; J D Jackson
Journal:  CMAJ       Date:  1999-01-12       Impact factor: 8.262

3.  The effects of initial drug choice and comorbidity on antihypertensive therapy compliance: results from a population-based study in the elderly.

Authors:  M Monane; R L Bohn; J H Gurwitz; R J Glynn; R Levin; J Avorn
Journal:  Am J Hypertens       Date:  1997-07       Impact factor: 2.689

4.  Continuation of initial antihypertensive medication after 1 year of therapy.

Authors:  B S Bloom
Journal:  Clin Ther       Date:  1998 Jul-Aug       Impact factor: 3.393

5.  Variations in compliance among hypertensive patients by drug class: implications for health care costs.

Authors:  J A Rizzo; W R Simons
Journal:  Clin Ther       Date:  1997 Nov-Dec       Impact factor: 3.393

6.  The impact of side effects on hypertension management: a Japanese survey.

Authors:  H Toyoshima; K Takahashi; T Akera
Journal:  Clin Ther       Date:  1997 Nov-Dec       Impact factor: 3.393

7.  Changes in antihypertensive therapy--the role of adverse effects and compliance.

Authors:  R Düsing; B Weisser; T Mengden; H Vetter
Journal:  Blood Press       Date:  1998-11       Impact factor: 2.835

Review 8.  Stepped care for hypertension: are the assumptions valid?

Authors:  J J Caro
Journal:  J Hypertens Suppl       Date:  1997-12

Review 9.  Existing treatment strategies: does noncompliance make a difference?

Authors:  J J Caro; J L Speckman
Journal:  J Hypertens Suppl       Date:  1998-09

Review 10.  Role of patient compliance in clinical pharmacokinetics. A review of recent research.

Authors:  J Urquhart
Journal:  Clin Pharmacokinet       Date:  1994-09       Impact factor: 6.447

View more
  11 in total

1.  [Cost reduction with project based prescription of generic ACE inhibitors].

Authors:  Michael Wolzt; Gerald Ohrenberger; Berthold Reichardt
Journal:  Wien Klin Wochenschr       Date:  2003-01-31       Impact factor: 1.704

2.  Perceived information needs and non-adherence: evidence from Greek patients with hypertension.

Authors:  Charitini Stavropoulou
Journal:  Health Expect       Date:  2011-04-18       Impact factor: 3.377

3.  Predictors of 12-month outcome in smokers who received bupropion sustained-release for smoking cessation.

Authors:  Gary E Swan; Lisa M Jack; Harold S Javitz; Tim McAfee; Jennifer B McClure
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

Review 4.  Sexual dysfunction in male patients with hypertension: influence of antihypertensive drugs.

Authors:  Rainer Düsing
Journal:  Drugs       Date:  2005       Impact factor: 9.546

5.  Choice of initial antihypertensive drugs and persistence of drug use--a 4-year follow-up of 78,453 incident users.

Authors:  Randi Selmer; Hege Salvesen Blix; Knud Landmark; Asmund Reikvam
Journal:  Eur J Clin Pharmacol       Date:  2012-03-18       Impact factor: 2.953

Review 6.  Compliance and persistence with newer antihypertensive agents.

Authors:  William C Gerth
Journal:  Curr Hypertens Rep       Date:  2002-12       Impact factor: 5.369

7.  Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories.

Authors:  Bernard Vrijens; Gäbor Vincze; Paulus Kristanto; John Urquhart; Michel Burnier
Journal:  BMJ       Date:  2008-05-14

8.  Reducing adverse self-medication behaviors in older adults with the Next Generation Personal Education Program (PEP-NG): Design and methodology.

Authors:  Patricia J Neafsey; Elizabeth Anderson; Craig Coleman; Carolyn A Lin; Cyr E M'lan; Stephen Walsh
Journal:  Patient Prefer Adherence       Date:  2009-11-29       Impact factor: 2.711

9.  A pilot program at the worksite to reduce adverse self-medication behaviors.

Authors:  Patricia J Neafsey; Gregory Lutkus; Jessica Newcomb; Elizabeth Anderson
Journal:  Patient Prefer Adherence       Date:  2009-11-03       Impact factor: 2.711

10.  Application in the STRATHE trial of a score system to compare the efficacy and the tolerability of different therapeutic strategies in the management of hypertension.

Authors:  Bernard Waeber; Jean-Jacques Mourad
Journal:  Vasc Health Risk Manag       Date:  2008
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.